Dr. Swee Lay Thein and Dr. Stuart Orkin were awarded the 2026 Breakthrough Prize in Life Sciences for pioneering research that enabled the first CRISPR-based gene editing therapy for sickle cell disease, a breakthrough now offering potential functional cure for patients with this inherited blood disorder affecting millions globally, particularly in sub-Saharan Africa, India, and among populations of African descent in the Americas and Europe.
How CRISPR Therapy Corrects the Sickle Cell Mutation at the Genetic Level
The therapy, exagamglogene autotemcel (exa-cel), developed from foundational work by Dr. Orkin at Boston Children’s Hospital and Dr. Thein at King’s College London, targets the BCL11A gene—a transcriptional repressor of fetal hemoglobin. By using CRISPR-Cas9 to edit hematopoietic stem cells ex vivo, the treatment reduces BCL11A expression, thereby reactivating fetal hemoglobin production. This compensates for defective adult hemoglobin (HbS), preventing red blood cell sickling, vaso-occlusive crises, and organ damage. The mechanism does not correct the HBB gene mutation directly but achieves phenotypic correction through fetal hemoglobin reactivation, a strategy validated in the CLIMB SCD-121 trial.
In Plain English: The Clinical Takeaway
- This one-time treatment reprograms a patient’s own stem cells to produce healthy fetal hemoglobin, reducing or eliminating painful sickle cell crises.
- In clinical trials, over 90% of patients remained free of vaso-occlusive crises for at least 12 months post-treatment, with many able to stop regular blood transfusions.
- While not yet universally available, the therapy represents a landmark shift from lifelong symptom management toward potential disease modification for eligible patients.
Global Access and Regulatory Pathways: From FDA Approval to Equity Challenges
In December 2023, the U.S. Food and Drug Administration (FDA) approved exa-cel for patients aged 12 and older with recurrent vaso-occlusive crises, marking the first CRISPR-based therapy cleared for any genetic disease. The European Medicines Agency (EMA) followed with a positive opinion in early 2024, and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted approval in March 2024. Yet, access remains limited due to the therapy’s complexity—requiring chemotherapy conditioning, cell collection, genetic editing, and reinfusion—and its estimated cost of $2.2 million per patient in the U.S. In contrast, newborn screening and hydroxyurea remain the cornerstone of sickle cell management in low-resource settings, where over 75% of the 300,000 annual global births with sickle cell disease occur, primarily in sub-Saharan Africa.
Funding, Scientific Rigor, and Independent Validation
The foundational research identifying BCL11A as a therapeutic target was supported by grants from the National Institutes of Health (NIH), including the National Heart, Lung, and Blood Institute (NHLBI), and the Bill & Melinda Gates Foundation. The pivotal CLIMB SCD-121 trial, which led to FDA approval, was sponsored by CRISPR Therapeutics and Vertex Pharmaceuticals. Independent validation came from long-term follow-up studies published in New England Journal of Medicine, showing sustained fetal hemoglobin elevation and improved quality of life without off-target editing events in analyzed samples.
“The beauty of this approach lies in its precision: we’re not fixing a broken gene—we’re enhancing the body’s natural backup system. Fetal hemoglobin is safe, effective, and already present in infants; we’re just rekindling its production where it’s needed most.”
“For decades, hydroxyurea and transfusions were our best tools. Now, we have a curative option—but we must ensure it reaches the children in Lagos, Kinshasa, and Mumbai who bear the greatest burden. Equity in access is the next frontier.”
Clinical Outcomes and Safety Profile: What the Data Shows
| Outcome Measure | Exa-cel Group (N=35) | Control/Historical Benchmark |
|---|---|---|
| Freedom from vaso-occlusive crises ≥12 months | 94% (33/35) | Historical rate with standard care: ~10-15% |
| Reduction in transfusion dependence | 91% of transfusion-dependent patients became independent | Chronic transfusions required in ~20% of severe SCD patients |
| Treatment-related mortality | 0% | Myeloablative conditioning carries <5% mortality risk in qualified candidates |
| Mean fetal hemoglobin (% total hemoglobin) | 41.3% at 12 months | Baseline: <5%; therapeutic target: ≥20% |
Contraindications & When to Consult a Doctor
Exa-cel is not suitable for patients with active uncontrolled infections, recent malignancy, or organ failure that would preclude myeloablative conditioning with busulfan. Patients with significant cardiac, pulmonary, or renal impairment require individualized risk assessment. The conditioning regimen carries risks of infertility, secondary malignancy (though none observed in trials to date), and temporary cytopenias. Patients should seek immediate medical attention if they experience persistent fever, unexplained bleeding, or signs of infection post-treatment. Long-term monitoring for insertional mutagenesis and clonal hematopoiesis remains standard per FDA labeling.
The Path Forward: Scaling Access and Next-Generation Approaches
While exa-cel offers transformative potential, its high cost and infrastructure demands limit widespread adoption. Researchers are exploring in vivo CRISPR delivery to eliminate the require for ex vivo processing, which could reduce complexity and expense. The NIH’s Cure Sickle Cell Initiative aims to accelerate affordable gene-based therapies, with several preclinical programs targeting fetal hemoglobin regulators or direct HBB correction. Until then, expanding access to hydroxyurea, penicillin prophylaxis, and transcranial Doppler screening remains critical for reducing global morbidity and mortality, particularly in high-burden regions where newborn screening coverage is still below 50% in many countries.
References
- Frangoul H, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Beta-Thalassemia. New England Journal of Medicine. 2021;384:251-260. Doi:10.1056/NEJMoa2031054.
- Bauer DE, et al. Targeting BCL11A to Treat Sickle Cell Disease and Beta-Thalassemia. Nature Medicine. 2013;19:1047-1052. Doi:10.1038/nm.3295.
- U.S. Food and Drug Administration. FDA Approves First Gene Therapy for Sickle Cell Disease. Press Release. December 8, 2023. Https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-sickle-cell-disease.
- National Institutes of Health. Cure Sickle Cell Initiative. Https://www.nhlbi.nih.gov/sickle-cell/cure-initiative.
- World Health Organization. Sickle Cell Disease. Fact Sheet. Updated March 2024. Https://www.who.int/news-room/fact-sheets/detail/sickle-cell-disease.
